KRAS G12D

Overview

KRAS G12D is a point mutation in the KRAS gene that substitutes aspartate for glycine at codon 12. Glycine-12 sits in the P-loop that cradles the γ-phosphate of bound GTP, and the larger aspartate side chain obstructs the arginine finger that GTPase-activating proteins insert to catalyze hydrolysis. The mutant therefore retains residual intrinsic GTPase activity but is effectively deaf to GAP stimulation, so it accumulates in the GTP-bound state and signals continuously through the RAF–MEK–ERK cascade, the PI3K/AKT/mTOR pathway, and RAL guanine nucleotide exchange factors, driving proliferation and survival independently of upstream receptor input.

It is among the most prevalent oncogenic drivers in human cancer. In pancreatic ductal adenocarcinoma, where KRAS is mutated in over 90% of tumors, G12D is the single most common variant at roughly 35–45% of cases; it is also frequent in colorectal cancer and appears in lung adenocarcinoma, though there KRAS G12C predominates.

G12D was long considered undruggable, and the reason is specific rather than general: picomolar affinity for GTP rules out competitive nucleotide inhibitors, and the covalent strategy that yielded the first approved KRAS drugs depends on a reactive cysteine that G12C provides and G12D does not. Progress has come from non-covalent inhibitors that exploit the aspartate itself, from RAS(ON) compounds that act on the active GTP-bound state through a cyclophilin A complex rather than on the inactive state, and from targeted protein degradation. In parallel, the mutant peptide is being pursued as a public neoantigen through T cell receptor–engineered cell therapy and vaccines, since a recurrent single substitution presented on a shared HLA allele is the same target for many patients. Adaptive reactivation of ERK signaling is the recurring obstacle to all of the direct approaches, which is why combinations with upstream or downstream inhibitors are under active study.

Recent Publications Summary

Selective KRAS G12D inhibitors have emerged as a major focus in cancer therapeutics, particularly for metastatic pancreatic ductal adenocarcinoma. A phase III trial of the pan-RAS inhibitor daraxonrasib demonstrated nearly doubled median overall survival (13.2 vs. 6.6 months) and progression-free survival compared to chemotherapy in second-line mPDAC 42571010Aug. Complementing these advances, multiple allele-specific KRAS G12D inhibitors are advancing through clinical development, including DN022150, RNK08594, and GFH375, which have shown encouraging early clinical data across solid tumors such as pancreatic ductal adenocarcinoma and non-small cell lung cancer 42299111Jun42571010Aug. Combination strategies pairing G12D inhibitors with immunotherapy and antibody-drug conjugates are also being evaluated to enhance therapeutic benefit 42571010Aug. Additionally, a PROTAC drug designed to degrade mutant KRAS G12D demonstrated tumor responses in a phase I trial with limited toxicity, prompting advancement to combination and later-stage studies 41911322Mar.

Multiple drug discovery approaches have identified novel inhibitors of KRAS G12D. Virtual screening combined with molecular dynamics simulations identified natural compounds, including mangiferin and hesperetin 7-O-glucoside, as potential inhibitors with predicted binding affinities comparable to reference compounds 42126708May. An active fragment assembly strategy yielded compound 10b, which exhibited significant inhibitory activity against pancreatic cancer cells harboring KRAS G12D mutations and effectively downregulated phosphorylated Raf1, AKT, and ERK levels 41931988Apr.

CRISPR-based approaches represent an emerging therapeutic avenue for targeting KRAS G12D. Base editing strategies enable precise inactivation of KRAS G12D through engineered deaminases that introduce single-nucleotide changes without generating double-strand breaks 41833894Mar. CRISPR-supported nanoparticle systems, such as CRISPR-curcumin nanoparticles combined with ultrasound-mediated permeabilization, have been designed to silence KRAS G12D while enhancing tumor-suppressor gene expression (TP53, PTEN) in metastatic pulmonary cancer models 41882965Mar.

Adaptive resistance to KRAS G12D inhibition remains a significant challenge to sustained therapeutic benefit. EGFR-mediated reactivation of the RAS-MAPK pathway has been identified as a potential mechanism of resistance in some tumor types, suggesting that combination vertical pathway inhibition strategies may improve durability of response 41801133Mar. KRAS-driven PDIA6 expression has been shown to suppress immunogenic cell death and promote immune checkpoint blocker resistance in PDAC, with PDIA6 inhibition improving ICB response in preclinical models 41667239Feb.

What Changes, What Holds

1. KRAS G12D inhibitors achieve clinically meaningful survival gains in second-line metastatic pancreatic cancer
REINFORCES Daraxonrasib's doubled median overall survival compared to chemotherapy confirms the therapeutic progress the Overview anticipated would emerge from non-covalent inhibitors and related approaches. However, the durability ceiling imposed by adaptive ERK reactivation remains the defining clinical obstacle. Longer follow-up and sequential strategies are now focal questions 42571010Aug.

2. Novel KRAS G12D inhibitors suppress downstream signaling in vitro and in cell models
REINFORCES Mangiferin, hesperetin, and compound 10b represent additional compounds discovered through structure-based and fragment-assembly approaches, each inhibiting G12D through non-covalent mechanisms. The specific agents differ, but the underlying strategy—exploiting the aspartate side chain to block signaling—remains the established territory the Overview identified as promising. Such screening efforts are incremental expansions of known approaches 42126708May41931988Apr.

3. CRISPR-mediated inactivation of KRAS G12D shows efficacy in preclinical cancer models
NEW DIRECTION Base editing and CRISPR-nanoparticle systems represent therapeutic approaches absent from the Overview, which discusses non-covalent inhibitors, protein degradation, and neoantigen strategies but not direct genetic correction. Mutation reversal through precision editing opens a mechanistically distinct path—silencing the mutant allele entirely rather than merely blocking its product. Efficacy in cell models suggests clinical development is warranted, adding a new therapeutic class to the G12D armamentarium 41833894Mar41882965Mar.

4. PDIA6-driven immune evasion represents a distinct resistance pathway to KRAS G12D therapy
NEW DIRECTION PDIA6-mediated suppression of immunogenic cell death identifies an escape mechanism the Overview does not address, orthogonal to the adaptive ERK reactivation it already names as the primary obstacle (here shown operating via EGFR). While the baseline anticipates combating MAPK reactivation through upstream and downstream inhibition, immune evasion represents a separate resistance class. PDIA6 inhibition therefore emerges as a distinct therapeutic target for combination with checkpoint blockers and direct G12D inhibitors 41667239Feb41801133Mar.

Overview update candidates: Phase III selective KRAS G12D inhibitor efficacy in advanced PDAC; CRISPR-based allele inactivation; PDIA6-mediated immunotherapy resistance mechanisms.